In this second part of our focus on ocular diseases, we look at the latest developments taking place in the treatment of central vision disorders such as age-related macular degeneration (AMD). This disease, along with cataracts, diabetic retinopathy, and glaucoma, represents a considerable economic burden to the health systems of developed and developing countries . . . and the situation is predicted to get worse.